确定异常性肺纤维化潜在的药物标:基于可药物基因的孟德尔随机化研究
Zetao Liu1,2, Zhiyu Peng1,2, Huahang Lin1,2
1Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Respiratory research
|May 23, 2024
概括
介质素-7 (IL-7) 可能是异常性肺纤维化 (IPF) 的有希望的药物标. 这项研究确定IL-7是减少IPF风险和改善肺功能的潜在治疗标.
科学领域:
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
- 肺部病理学 肺部病理学
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺病,原因不明.
- 发现新的药物点对于治疗IPF和改善患者的治疗结果至关重要.
研究的目的:
- 为了确定与IPF易感性和进展相关的可用药物基因.
- 通过基因关联研究,探索IPF的潜在治疗点.
主要方法:
- 利用孟德尔的随机化分析与可药物基因的cis表达量化特征位置 (cis-eQTL) 数据以及IPF的全基因组关联研究 (GWAS) 数据.
- 进行了局部化分析,以评估基因表达和IPF之间的共同因果变异.
- 使用蛋白质定量特征位置 (pQTL) 分析验证的发现.
主要成果:
- 确定了45个可用药物的基因,与IPF易感性有显著的关联.
- 在IPF患者中发现了基因表达和强迫生命能力 (FVC) 降低以及肺部对一氧化碳 (DLco) 的扩散能力之间的关联.
- IL-7和ABCB2显示了与IPF潜在的共同因果变异; IL-7水平升高与IPF风险降低有关.
结论:
- 介质素-7 (IL-7) 成为缓解IPF风险的非常有前途的药物标.
- 这项研究为未来的IPF药物开发策略提供了宝贵的见解.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


